Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405587 · ClinicalTrials.gov registry record · Phase 1
Safety Study of PLX4032 in Patients With Solid Tumors
A Phase 1 study, sponsored by Plexxikon.
- Completed
- Registry status
- Phase 1
- Development phase
- 109
- Enrollment target
NCT00405587 is a Phase 1 study that has completed, run by Plexxikon. The registered enrollment target is 109 participants.
The verdict
NCT00405587, a Phase 1 study, has completed, sponsored by Plexxikon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant melanoma who have the V600E BRAF oncogenic mutation.
Interventions
- DRUG PLX4032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2006-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405587
The ClinicalTrials.gov registry entry for NCT00405587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Plexxikon, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX4032 is the first listed.
NCT00405587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00405587 about?
NCT00405587 is a clinical study titled "Safety Study of PLX4032 in Patients With Solid Tumors". The primary objective of this FIH study is to assess the safety and pharmacokinetics of PLX4032 in patients with solid tumors. The secondary objective is to assess the pharmacodynamic activity in paired biopsy specimens obtained from patients with malignant melanoma who have the V600E BRAF oncogenic...
What is the current status of trial NCT00405587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2006-11. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00405587?
The interventions under investigation include: PLX4032 (DRUG).
Who is sponsoring clinical trial NCT00405587?
This trial is sponsored by Plexxikon, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.